Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
News Jun 28, 2016
For this collaboration, Kenneth Keiler, professor of biochemistry and molecular biology and principal investigator on the project, and his team will screen “orphan” drug compounds that were identified by TB Alliance, a nonprofit organization dedicated to developing better tuberculosis drugs, and GSK, a global healthcare company. These orphan compounds had been developed to fight other diseases and did not work for their original purpose. Now Keiler aims to discover if they may be viable to be made into effective tuberculosis drugs.
Keiler’s team was chosen for this collaboration because of his work discovering “trans-translation,” a process in bacteria that ensures protein synthesis is not interrupted. Keiler believes disrupting the trans-translation process is key to stopping the growth of bacterial diseases like tuberculosis.
Tuberculosis affects two billion people worldwide and can be found in every country in the world. However, the impact of tuberculosis is felt most strongly in resource-poor nations where patients might not have access to both the medication or regular medical oversight to ensure effective treatment of tuberculosis. “Without constant monitoring, people tend to stop taking the drugs,” said Keiler.
Even in the U.S., compliance with taking the full course of tuberculosis medication can be a problem, leading to drug-resistant strains of tuberculosis. Part of this is due to the length of treatment time for the disease, said Keiler. Current treatment for tuberculosis involves a cocktail of antibiotics that must be taken for at least six months (but as long as two years) to be effective. Keiler’s end goal with this research is to be able to shorten the treatment from six months to two weeks using antibiotics made from molecules that disrupt trans-translation.
So far, Keiler’s team has identified three families of compounds donated from GSK that could be very promising for new tuberculosis drug development.
“We identified several compounds that inhibit the protein quality control pathway that we study,” said Keiler. “We have also learned some important basic science about the quality control pathway from the activity of the molecules.”
Keiler’s team is currently finishing the molecular experiments and further testing for drug development is planned.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE